Working... Menu

ViVEXX Carotid Revascularization Trial (VIVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00417963
Recruitment Status : Completed
First Posted : January 4, 2007
Results First Posted : July 20, 2011
Last Update Posted : March 1, 2017
Information provided by (Responsible Party):
C. R. Bard

Brief Summary:
To evaluate the safety and efficacy of the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System in the treatment of extracranial carotid artery stenosis in patients at high risk for carotid endarterectomy.

Condition or disease Intervention/treatment Phase
Carotid Artery Stenosis Device: Carotid Artery Stenting Phase 3

Detailed Description:
Patients with clinically significant stenosis within the common and/or internal carotid artery who are at high risk for carotid endarterectomy and are amenable to percutaneous treatment including embolic protection, balloon angioplasty and the carotid stent placement.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 407 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The ViVEXX Carotid Revascularization Trial (VIVA) for High Surgical Risk Patients With Extracranial Carotid Artery Stenosis Using the Bard ViVEXX Carotid Stent and Emboshield BareWire Rapid Exchange Embolic Protection System
Study Start Date : October 2005
Actual Primary Completion Date : January 2009
Actual Study Completion Date : March 2010

Arm Intervention/treatment
Experimental: stent placement in the carotid artery
placement of a bare metal stent for treatment of carotid artery stenosis
Device: Carotid Artery Stenting
placement of a bare metal stent at sites of stenosis in the carotid artery
Other Name: CAS

Primary Outcome Measures :
  1. Percentage of Patients Experiencing Major Adverse Events (MAE) [ Time Frame: 365 days from implantation ]
    A composite of major adverse events (MAE) including any death, any stroke and/or myocardial infarction occurring during the first 30 days post-procedure and ipsilateral stroke between 31 and 365 days post procedure.

Secondary Outcome Measures :
  1. Number of Participants Experiencing Target Lesion Revascularization(s) (TLR) [ Time Frame: 12 months from implantation ]
    Number of participants experiencing a Target lesion revascularization(s) up to 12 months after implantation

  2. Number of Patients Experiencing Access Site Complications [ Time Frame: 30 days following implantation ]
    Access site complications requiring blood transfusion (> 1 unit) or open surgical repair.

  3. Number of Participants Experiencing Stroke Related Neurologic Deficit [ Time Frame: 30 days from implantation ]
    Number of participants experiencing stroke related neurologic deficit persisting at 30 days and attributed to the index procedure.

  4. Number of Participants Experiencing Device Success [ Time Frame: at time of implantation ]
    Number of participants with successful delivery and deployment of device with <50% residual stenosis.

  5. Number of Participants Experiencing Lesion Success [ Time Frame: at time of implantation ]
    number of participants experiencing achievement of <50% final residual diameter stenosis in the stented segment using the VIVEXX Carotid Stent and the Emboshield Embolic Protection System.

  6. Number of Participants Experiencing Restenosis [ Time Frame: 12 months after implantation ]
    Number of participants experiencing Restenosis following placement of the ViVexx Carotid Stent.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient has a symptomatic or asymptomatic carotid artery stenosis that meets one of the following criteria:

    • Symptomatic: > than or = to 50% carotid stenosis by angiography and a history of non-disabling stroke, transient ischemic attack (TIA) in the hemisphere supplied by the target vessel within 180 days of the procedure.
    • Asymptomatic: > than or = to 80% carotid stenosis by angiography without neurological symptoms.
  • High risk for carotid endarterectomy: anatomical and co-morbid.

Exclusion Criteria:

  • History of symptoms of stroke or TIA within 24 hours of the procedure
  • Extensive or diffuse atherosclerotic disease
  • Severe vascular tortuosity or anatomy that would preclude the safe introduction of the device

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00417963

Sponsors and Collaborators
C. R. Bard
Layout table for investigator information
Principal Investigator: Kenneth Rosenfield, MD Massachusetts General Hospital

Layout table for additonal information
Responsible Party: C. R. Bard Identifier: NCT00417963     History of Changes
Other Study ID Numbers: BPV-VX-1502
First Posted: January 4, 2007    Key Record Dates
Results First Posted: July 20, 2011
Last Update Posted: March 1, 2017
Last Verified: January 2017

Keywords provided by C. R. Bard:

Additional relevant MeSH terms:
Layout table for MeSH terms
Constriction, Pathologic
Carotid Stenosis
Pathological Conditions, Anatomical
Carotid Artery Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases